These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6424970)

  • 21. Temporal coupling of luteinizing hormone and follicle stimulating hormone secretion in polycystic ovary syndrome.
    Zarković M; Cirić J; Penezić Z; Trbojević B; Drezgić M
    Gynecol Endocrinol; 2001 Oct; 15(5):381-8. PubMed ID: 11727361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hirsutism: metabolic effects of two commonly used oral contraceptives and spironolactone.
    Wild RA; Demers LM; Applebaum-Bowden D; Lenker R
    Contraception; 1991 Aug; 44(2):113-24. PubMed ID: 1893706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daily serum follicle-stimulating hormone, luteinizing hormone, and plasma testosterone and androstenedione in hirsute women with polycystic sclerotic ovaries: effects of diethylstilbestrol and norethindrone acetats.
    Daane TA; Dignam WJ; Frankland MV; Simmer HH; Parlow AF
    Am J Obstet Gynecol; 1973 Oct; 117(3):392-9. PubMed ID: 4729733
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of hirsutism with a gonadotropin-releasing hormone agonist (nafarelin).
    Andreyko JL; Monroe SE; Jaffe RB
    J Clin Endocrinol Metab; 1986 Oct; 63(4):854-9. PubMed ID: 2943756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial.
    Cusan L; Dupont A; Gomez JL; Tremblay RR; Labrie F
    Fertil Steril; 1994 Feb; 61(2):281-7. PubMed ID: 8299783
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The treatment of essential hirsutism in women with cyproterone acetate and ethinyl estradiol. Clinical and endocrine effects in 10 cases.
    Frey H; Aakvaag A
    Acta Obstet Gynecol Scand; 1981; 60(3):295-300. PubMed ID: 6455899
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dexamethasone and spironolactone in the treatment of non-tumorous hyperandrogenism.
    Prezelj J; Kocijancic A; Andolsek L
    Gynecol Endocrinol; 1989 Dec; 3(4):281-8. PubMed ID: 2516705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of combined cyproterone acetate-ethinyl oestradiol therapy on serum levels of dehydroepiandrosterone, androstenedione, and testosterone in hirsute women.
    Frölich M; Lachinsky N; Moolenaar AJ
    Acta Endocrinol (Copenh); 1977 Feb; 84(2):333-42. PubMed ID: 138326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of idiopathic hirsute women with two combinations of cyproterone acetate.
    Salva P; Morer F; Ordoñez J; Rodriguez J
    Int J Clin Pharmacol Res; 1983; 3(2):129-35. PubMed ID: 6237068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antiandrogenic properties of spironolactone. Clinical trial in the management of female hirsutism.
    Messina M; Manieri C; Biffignandi P; Massucchetti C; Novi RF; Molinatti GM
    J Endocrinol Invest; 1983 Feb; 6(1):23-7. PubMed ID: 6404979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of spironolactone-oral contraceptive versus cyproterone acetate-estrogen regimens in the treatment of hirsutism.
    Erenus M; Yücelten D; Gürbüz O; Durmuşoğlu F; Pekin S
    Fertil Steril; 1996 Aug; 66(2):216-9. PubMed ID: 8690104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regression of Polycystic Ovaries by Estrogen Therapy.
    Gambrell RD
    Obstet Gynecol; 1976 May; 47(5):569-74. PubMed ID: 131262
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism.
    Erenus M; Gürbüz O; Durmuşoğlu F; Demirçay Z; Pekin S
    Fertil Steril; 1994 Apr; 61(4):613-6. PubMed ID: 8150100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic effects of spironolactone in polycystic ovary syndrome.
    Milewicz A; Silber D; Kirschner MA
    Obstet Gynecol; 1983 Apr; 61(4):429-32. PubMed ID: 6828272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hormonal and clinical effects of chronic gonadotropin-releasing hormone agonist treatment in polycystic ovary syndrome.
    Szilágyi A; Homoki J; Bellyei S; Szabó I
    Gynecol Endocrinol; 2000 Oct; 14(5):337-41. PubMed ID: 11109973
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of a long-acting gonadotropin-releasing hormone analog on the pituitary-ovarian-adrenal axis in women with severe hirsutism.
    Castelo-Branco C; Martínez de Osaba MJ; Martínez S; Fortuny A
    Metabolism; 1996 Jan; 45(1):24-7. PubMed ID: 8544772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism.
    Keleştimur F; Everest H; Unlühizarci K; Bayram F; Sahin Y
    Eur J Endocrinol; 2004 Mar; 150(3):351-4. PubMed ID: 15012621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome.
    Gökmen O; Senöz S; Gülekli B; Işik AZ
    Gynecol Endocrinol; 1996 Aug; 10(4):249-55. PubMed ID: 8908525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of linear relationship between hyperinsulinaemia and hyperandrogenism.
    Toscano V; Bianchi P; Balducci R; Guglielmi R; Mangiantini A; Lubrano C; Sciarra F
    Clin Endocrinol (Oxf); 1992 Feb; 36(2):197-202. PubMed ID: 1533185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mild adrenal and ovarian steroidogenic abnormalities in hirsute women without hyperandrogenemia: does idiopathic hirsutism exist?
    Escobar-Morreale HF; Serrano-Gotarredona J; García-Robles R; Sancho J; Varela C
    Metabolism; 1997 Aug; 46(8):902-7. PubMed ID: 9258272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.